Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Levacetylleucine→

Levacetylleucine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1188-21-2
Molecular formula
C8H15NO3
Molecular weight
173.21 g/mol
Drug class
Acetylated L-leucineneurometabolic therapy for selected inherited neurological disorders
Mechanism of action
The mechanism is not fully established. Acetylated leucine may modulate neuronal energy metabolism, membrane stability and cerebellar network function; no single molecular target is confirmed as the clinical mechanism.
Indications / reported uses
  • Treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and paediatric patients weighing at least 15 kg under the US AQNEURSA indication
  • Treatment of ataxia-telangiectasia in adults and paediatric patients weighing at least 15 kg under the US indication where authorised; verify current label wording for disease-specific use

Sources: US DailyMed — AQNEURSA (levacetylleucine) · US FDA prescribing information · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Acetylated L-leucine; neurometabolic therapy for selected inherited neurological disorders

Mechanism of action

The mechanism is not fully established. Acetylated leucine may modulate neuronal energy metabolism, membrane stability and cerebellar network function; no single molecular target is confirmed as the clinical mechanism.

General use cases

  • Treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and paediatric patients weighing at least 15 kg under the US AQNEURSA indication
  • Treatment of ataxia-telangiectasia in adults and paediatric patients weighing at least 15 kg under the US indication where authorised; verify current label wording for disease-specific use

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Levacetylleucine Environmental Risk Assessment (ERA) (the Levacetylleucine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.